An interventional study of Exercise group and Control group in Testicular Neoplasms, sponsored by Oslo University Hospital. Terminated at 1 site in Norway. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-01-26.
Sponsored by Oslo University Hospital · Not applicable, Interventional, and Supportive care
The present study examine the effects of an aerobic and strength training program on cardiorespiratory fitness in testicular cancer (TC) patients during chemotherapy. Half of the participants will receive the exercise program and the other half will receive one individual lifestyle counseling session. The investigators hypothesize that TC patients in the exercise group will have less reduction in cardiorespiratory fitness during chemotherapy treatment compared to patients in the control group.
Testicular cancer (TC) patients receiving chemotherapy often experience troublesome side-effects during and after treatment. Both aerobic and strength exercise have showed beneficial effects on side-effects during and after treatment in other cancer diagnosis. Knowledge of the effects of physical exercise during and after chemotherapy in TC patients is insufficient and studies are needed. The primary aim is to examine the effects of physical exercise on cardiorespiratory fitness in TC patients during chemotherapy. Secondary aims are to examine the effects of physical exercise on other secondary health outcomes during and three and twelve months after chemotherapy.
The present study is a randomized controlled trial comparing a tailored exercise program consisting of aerobic and strength training during chemotherapy to a control group receiving one individual lifestyle counseling session during the first chemotherapy cycle. The TC patients will be included and assessed before the first cycle of chemotherapy and further assigned to either a exercise group or a control group. The intervention will last for 9 or 12 weeks (depending on the number of bleomycin, etoposide, cisplatin (BEP)/etoposide, cisplatin (EP) cycles received) and it will consists of two-three one-hour sessions per week mostly supervised by a personal trainer. All variables will be assessed pre- and post-intervention, and at three and 12 months follow-up.
189 studies on the registry are indexed under Testicular Neoplasms; 53 are open to participants now.
This study's enrollment of 19 is below the median of 59 across 122 interventional studies indexed under Testicular Neoplasms.
Browse Testicular Neoplasms studies →Oslo University Hospital is the lead sponsor of 810 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Aerobic- and Strength Training program
Behavioral: Exercise group
One lifestyle counseling session
Behavioral: Control group
The intervention will be conducted during chemotherapy and tailored for each patient. The program will include 1) weight bearing aerobic exercises to maintain the oxygen transport and thereby reduce the decline in VO2max during chemotherapy and 2) strength training exercises to maintain muscle mass and muscle strength. The intervention will last for 9 or 12 weeks, depending on the number of BEP/EP cycles received. The program will consist of two-three one-hour exercise sessions per week, of which most supervised by a personal trainer. The intensity of each exercise sessions will varies from easy (warm-up: 60-70 % of peak heart rate) to moderate/high (between aerobic intervals 60-70% of peak heart rate and during aerobic intervals 85-95 %).
The control group will receive one individual lifestyle counseling session during the first chemotherapy cycle and can perform all activities that they have planned to do during chemotherapy.
VO2peak (directly by modified Balke protocol on a treadmill)
Differences in change in VO2peak from pre- to post-intervention between the exercise group and the control group.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13)
VO2peak (directly by modified Balke protocol on a treadmill)
Differences in change in VO2peak from pre-post-intervention to three and 12 months follow-ups between the exercise group and the control group. Examine potential prognostic factors of reduced VO2peak at 12 months follow-up in all participants.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
Spirometry
Differences in change in pulmonary function (lung capacity, lung volume, diffusion capacity) from pre- to post-intervention and at three and 12 months follow-ups between the exercise group and the control group.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
One-repetition maximum muscle strength test (1RM)
Differences in change in muscle strength from pre- to post-intervention and at three and 12 months follow-ups between the exercise group and the control group.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
Dual-energy X-ray absorptiometry (DXA)
Differences in change in lean body mass and fat mass from pre- to post-intervention and at three and 12 months follow-ups between the exercise group and the control group. Examine potential prognostic factors of unhealthy body composition at 12 months follow-up in all participants.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
Body mass index (BMI)
Differences in change in BMI from pre- to post-intervention and at three and 12 months follow-ups between the exercise group and the control group. Examine potential prognostic factors of unhealthy BMI at 12 months follow-up in all participants.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
Hip- and Waist circumferences
Differences in change in hip- and waist circumferences from pre- to post-intervention and at three and 12 months follow-ups between the exercise group and the control group.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
Godin Leisure Time Exercise Questionnaire (GLTEQ)
Differences in change in physical exercise from pre- to post-intervention and at three and 12 months follow-ups between the exercise group and the control group. Examine potential prognostic factors of being inactive at 12 months follow-up in all participants.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
Sick leave and Work Ability Index (WAI)
Differences in work ability and sick leave from pre- to post-intervention and at three and 12 months follow-ups between the exercise group and the control group. Examine potential prognostic factors of reduced work ability at 12 months follow-up in all participants.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
The European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) C-30
Differences in change in health related quality of life (HRQOL) from pre- to post-intervention and at three and 12 months follow-ups between the exercise group and the control group. Examine potential prognostic factors of having reduced HRQOL at 12 months follow-up in all participants.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
Fatigue questionnaire
Differences in change in fatigue from pre- to post-intervention and at three and 12 months follow-ups between the exercise group and the control group. Examine potential prognostic factors of having fatigue at 12 months follow-up in all participants.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
Hospital and Anxiety and Depression Scale (HADS)
Differences in change in anxiety and depression from pre- to post-intervention and to three and 12 months follow-ups between the exercise group and the control group. Examine potential prognostic factors of having anxiety and depression at 12 months follow-up in all participants.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
Markers for inflammation, endothelia dysfunction, thrombosis and cardiovascular diseases and cisplatin
Differences in change in blood tests from pre- to post intervention and at three and 12 months follow-up in the exercise group and the control group. Examine potential risk factors for endothelia dysfunction, activated coagulation and thrombosis and cardiovascular diseases (metabolic syndrome) at 12 months follow-up in all participants.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13) and at three and 12 months follow-ups
Safety and tolerability
Number of participants with adverse events during the exercise intervention.
Time frame: Pre-intervention (week 0) to post-intervention (week 10/13)
This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oslo University Hospital